Opening the door to innovation

mAbs

Volumn 6, Issue 4, 2014, Pages 812-819

  Schuurman, Janine ^a   Graus, Yvo F ^a   Labrijn, Aran F ^a   Ruuls, Sigrid R ^a   Parren, Paul Whi ^a  

^a GENMAB   (Netherlands)

Author keywords

Bispecific antibodies; Drug development; DuoBody technology; Fab arm exchange; Immunotherapy; Open innovation; Technology platform

Indexed keywords

IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY;

DRUG DEVELOPMENT; DRUG INDUSTRY; KNOWLEDGE; MEDICAL TECHNOLOGY; REVIEW; ANIMAL; DRUG APPROVAL; DRUG DESIGN; HUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG APPROVAL; DRUG DESIGN; HUMANS;

EID: 84903792987     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29004     Document Type: Review

References (62)

1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9:203-14; PMID:20168317
2. Herper M. The truly staggering cost of inventing new drugs. Forbes, 2012: http://www.forbes.com/sites /mat thewherper/2012/02/10/the-truly-staggering- cost-of-inventing-new-drugs/.
3. Strohl WR, Strohl LM. Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry. Woodhead Publishing, 2012.
4. Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov 2013; 12:87-90; PMID:23370234; http://dx.doi.org/10.1038/nrd3946
5. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 2012; 11:191-200; PMID:22378269; http://dx.doi.org/10.1038/nrd3681
6. Kessel M. The problems with today's pharmaceutical business--an outsider's view. Nat Biotechnol 2011; 29:27-33; PMID:21221096; http://dx.doi.org/10.1038/nbt.1748
7. Chesbourg H. Open Innovation: The New Imperative for creating and profiting from technology. Boston Harvard Business School Press, 2003.
8. Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013; 12:489-92; PMID:23812256; http://dx.doi.org/10.1038/ nrd4066
9. Mullard A. European lead factory opens for business. Nat Rev Drug Discov 2013; 12:173-5; PMID:23449292; http://dx.doi.org/10.1038/nrd3956
10. Mullard A. 2013 FDA drug approvals. Nat Rev Drug Discov 2014; 13:85-9; PMID:24481294; http://dx.doi.org/10.1038/nrd4239
11. Reichert JM. Antibodies to watch in 2014. MAbs 2014; 6:5-14; PMID:24284914; http://dx.doi.org/10.4161/mabs.27333
12. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; http://dx.doi.org/10.1126/science.342. 6165.1432
13. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100
14. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
15. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812-21; PMID:21047225; http://dx.doi.org/10. 1056/NEJMoa1002965
16. Pettit GR, Kamano Y, Fujii Y, Herald CL, Inoue M, Brown P, Gust D, Kitahara K, Schmidt JM, Doubek DL, et al. Marine animal biosynthetic constituents for cancer chemotherapy. J Nat Prod 1981; 44:482-5; PMID:7288444; http://dx.doi.org/10.1021/np50016a016
17. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778-84; PMID:12778055; http://dx.doi.org/10.1038/nbt832
18. Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol 2013; 17:385-92; PMID:23623807; http://dx.doi.org/10.1016/j.cbpa.2013.03.029
19. Graus YF, de Baets MH, Parren PW, Berrih-Aknin S, Wokke J, van Breda Vriesman PJ, Burton DR. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol 1997; 158:1919-29; PMID:9029134
20. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-7; PMID:17872445; http://dx.doi.org/10.1126/science.1144603
21. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt. 1553
22. Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J Immunol 2011; 187:3238-46; PMID:21841137; http://dx.doi.org/10.4049/jimmunol.1003336
23. Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ. Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry. Structure 2011; 19:1274-82; PMID:21893287; http://dx.doi.org/10.1016/j.str.2011.06.016
24. Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW. Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs 2013; 5:219-28; PMID:23406897; http://dx.doi.org/10.4161/mabs.23532
25. Rosati S, van den Bremer ET, Schuurman J, Parren PW, Kamerling JP, Heck AJ. In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs 2013; 5:917-24; PMID:23995615; http://dx.doi.org/10.4161/mabs.26282
26. Van de Winkel JG, Vink T, Schuurman J, Parren PW, Aalberse RC, Van der Neut Kolfschoten M. WO2008145142. Stable IgG4 antibodies. 2007.
27. Parren PW, Neijssen J, Labrijn AF, Schuurman J, Vink T, Van de Winkel JG, Loverix S, Lasters I. WO2010084197. Methods for producing mixtures of antibodies. 2009.
28. Parren PW, Schuurman J, Vink T, Bleeker WK, van de Winkel JG, Van Berkel PH, Beurskens FJ. WO2007059782. Recombinant monovalent antibodies and methods for production thereof. 2005.
29. Losen M, Martinez-Martinez P, De Baets MH, Graus YF, Schuurman J, Parren PW. WO2007068255. Use of effector-function-deficient antibodies for treatment of auto-immune diseases. 2005.
30. Beurskens FJ, Bleeker WK, Labrijn AF, Parren PW, Schuurman J, Van Berkel PH, Van de Winkel JG, Vink T. WO2008145137. Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering. 2007.
31. Schuurman J, Vink T, Van de Winkel JG, Labrijn AF, Parren PW, Beurskens FJ, Bleeker WK, Van Berkel PH. WO2008145141. Method for extending the half-life of exogenous or endogenous soluble molecules. 2007.
32. Schuurman J, Vink T, van de Winkel JG, Labrijn AF, Parren PW, Bleeker WK, Beurskens FJ, Van Berkel PH. WO2008145138. Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering. 2007.
33. Schuurman J, Vink T, Van de Winkel JG, Labrijn AF, Parren PW, Bleeker WK, Beurskens FJ, Van Berkel PH. WO2008145139. Fusion or linked proteins with extended half life. 2007.
34. Schuurman J, Vink T, Van de Winkel JG, Labrijn AF, Parren PW, Bleeker WK, Beurskens FJ, Van Berkel PH. WO2008145140. Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals. 2007.
35. Labrijn AF, Loverix S, Parren PW, Van de Winkel JG, Schuurman J, Lasters I. WO2010063785. Antibody variants having modifications in the constant region. 2008.
36. Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 2013; 5:962-73; PMID:23995617; http://dx.doi.org/10.4161/mabs.26233
37. Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas. 1220145110
38. De Goeij B, Labrijn AF, Meesters J, Neijssen J, Parren PW, Schuurman J, Strumane K, Van Berkel PH. WO2012143523. Bispecific antibodies against her2. 2011.
39. Gramer M, Kundu A, Van den Bremer ET, Van Kampen M, Priem P, Labrijn AF, Meesters J, Neijssen J, Schuurman J, Parren PW, et al. WO2013060867. Production of heterodimeric proteins. 2011.
40. Labrijn AF, Meesters J, Van den Bremer ET, Neijssen J, Van Berkel PH, De Goeij B, Vink T, Van de Winkel JG, Schuurman J, Parren PW. WO2011131746. Heterodimeric antibody Fc-containing proteins and methods for production thereof. 2010.
41. Neijssen J, Meesters J, De Goeij B, Labrijn AF, Parren PW, Schuurman J. WO2012143524. Bispecific antibodies against her2 and CD3. 2011.
42. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 2004; 111:66-74; PMID:14678200; http://dx.doi.org/10.1111/j.1365-2567.2004.01767.x
43. Lessl M, Schoepe S, Sommer A, Schneider M, Asadullah K. Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. Drug Discov Today 2011; 16:288-92; PMID:21129498; http://dx.doi.org/10.1016/j. drudis.2010.11.013
44. Margni RA, Binaghi RA. Nonprecipitating asymmetric antibodies. Annu Rev Immunol 1988; 6:535-54; PMID:3289577; http://dx.doi.org/10.1146/annurev.iy.06. 040188.002535
45. van der Zee JS, van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol 1986; 137:3566-71; PMID:3782791
46. Schuurman J, Van Ree R, Perdok GJ, Van Doorn HR, Tan KY, Aalberse RC. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 1999; 97:693-8; PMID:10457225; http://dx.doi.org/10.1046/j.1365-2567.1999.00845.x
47. King DJ, Adair JR, Angal S, Low DC, Proudfoot KA, Lloyd JC, Bodmer MW, Yarranton GT. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment. Biochem J 1992; 281:317-23; PMID:1736881
48. Schuurman J, Perdok GJ, Gorter AD, Aalberse RC. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38:1-8; PMID:11483205; http://dx.doi.org/10.1016/S0161-5890(01) 00050-5
49. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, Pedley B, Adair JR. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-8; PMID:8417368; http://dx.doi.org/10.1016/0161-5890(93)90432-B
50. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105:9-19; PMID:11849310; http://dx.doi.org/10.1046/j.0019-2805.2001.01341.x
51. Schuurman J, Labrijn AF, Parren PW. Fab-arm exchange: what's in a name? MAbs 2012; 4:636; PMID:22955209; http://dx.doi.org/10.4161/mabs.22075
52. Aalberse RC, Van der Neut Kolfschoten M, Labrijn AF, Parren PW, Schuurman J, Vink T, Van de Winkel JG. WO2008119353. Bispecific antibodies and methods for production thereof. 2007.
53. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39:469-77; PMID:19222496; http://dx.doi.org/ 10.1111/j.1365-2222.2009.03207.x
54. Rispens T, Ooijevaar-de Heer P, Bende O, Aalberse RC. Mechanism of immunoglobulin G4 Fabarm exchange. J Am Chem Soc 2011; 133:10302-11; PMID:21627172; http://dx.doi.org/10.1021/ja203638y
55. Davies AM, Rispens T, den Bleker TH, McDonnell JM, Gould HJ, Aalberse RC, Sutton BJ. Crystal structure of the human IgG4 C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Mol Immunol 2013; 54:1-7; PMID:23164605; http://dx.doi.org/10.1016/j.molimm.2012.10.029
56. Losen M, Martínez-Martínez P, Phernambucq M, Schuurman J, Parren PW, De Baets MH. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann N Y Acad Sci 2008; 1132:174-9; PMID:18567867; http://dx.doi.org/10.1196/annals.1405.034
57. Rispens T, den Bleker TH, Aalberse RC. Hybrid IgG4/IgG4 Fc antibodies form upon 'Fab-arm' exchange as demonstrated by SDS-PAGE or size-exclusion chromatography. Mol Immunol 2010; 47:1592-4; PMID:20299101; http://dx.doi.org/ 10.1016/j.molimm.2010.02.021
58. Rispens T, Davies AM, Ooijevaar-de Heer P, Absalah S, Bende O, Sutton BJ, Vidarsson G, Aalberse RC. Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. J Biol Chem 2014; 289:6098-109; PMID:24425871; http://dx.doi.org/10.1074/jbc.M113. 541813
59. Rosati S, Yang Y, Barendregt A, Heck AJ. Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry. Nat Protoc 2014; 9:967-76; PMID:24675736; http://dx.doi.org/10. 1038/nprot.2014.057
60. Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20:479-85; PMID:18577454; http://dx.doi.org/10.1016/j.coi.2008.05.010
61. Rispens T, Meesters J, den Bleker TH, Ooijevaar-De Heer P, Schuurman J, Parren PW, Labrijn A, Aalberse RC. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Mol Immunol 2013; 53:35-42; PMID:22784992; http://dx.doi.org/10. 1016/j.molimm.2012.06.012
62. Rispens T, Ooievaar-De Heer P, Vermeulen E, Schuurman J, van der Neut Kolfschoten M, Aalberse RC. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol 2009; 182:4275-81; PMID:19299726; http://dx.doi.org/10.4049/jimmunol.0804338